IL153948A0 - Apo-2l receptor agonist and cpt-11 synergism - Google Patents
Apo-2l receptor agonist and cpt-11 synergismInfo
- Publication number
- IL153948A0 IL153948A0 IL15394801A IL15394801A IL153948A0 IL 153948 A0 IL153948 A0 IL 153948A0 IL 15394801 A IL15394801 A IL 15394801A IL 15394801 A IL15394801 A IL 15394801A IL 153948 A0 IL153948 A0 IL 153948A0
- Authority
- IL
- Israel
- Prior art keywords
- cpt
- apo
- synergism
- receptor agonist
- methods
- Prior art date
Links
- 239000000018 receptor agonist Substances 0.000 title abstract 2
- 229940044601 receptor agonist Drugs 0.000 title abstract 2
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 abstract 1
- 108700012411 TNFSF10 Proteins 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 230000005907 cancer growth Effects 0.000 abstract 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22125600P | 2000-07-27 | 2000-07-27 | |
| PCT/US2001/023691 WO2002009755A2 (fr) | 2000-07-27 | 2001-07-27 | Synergisme de l'agoniste du recepteur de l'apo-2l et du cpt-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL153948A0 true IL153948A0 (en) | 2003-07-31 |
Family
ID=22827042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL15394801A IL153948A0 (en) | 2000-07-27 | 2001-07-27 | Apo-2l receptor agonist and cpt-11 synergism |
Country Status (12)
| Country | Link |
|---|---|
| EP (2) | EP2014303A2 (fr) |
| JP (1) | JP2004509078A (fr) |
| AT (1) | ATE415978T1 (fr) |
| AU (1) | AU2001279055A1 (fr) |
| CA (1) | CA2415473A1 (fr) |
| CY (1) | CY1108815T1 (fr) |
| DE (1) | DE60136816D1 (fr) |
| DK (1) | DK1303293T3 (fr) |
| ES (1) | ES2317924T3 (fr) |
| IL (1) | IL153948A0 (fr) |
| PT (1) | PT1303293E (fr) |
| WO (1) | WO2002009755A2 (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7361341B2 (en) | 2001-05-25 | 2008-04-22 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to trail receptors |
| US7348003B2 (en) | 2001-05-25 | 2008-03-25 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors |
| WO2004016753A2 (fr) * | 2002-08-15 | 2004-02-26 | Human Genome Sciences, Inc. | Anticorps se fixant de facon immunospecifique a des recepteurs trail |
| US7842668B1 (en) | 2001-11-13 | 2010-11-30 | Genentech, Inc. | Apo-2 ligand/trail formulations |
| EP1450847B1 (fr) | 2001-11-13 | 2010-09-29 | Genentech, Inc. | Compositions à base de APO2 ligand/TRAIL et leur utilisation |
| US7741285B2 (en) | 2001-11-13 | 2010-06-22 | Genentech, Inc. | APO-2 ligand/trail formulations |
| EP2500032A1 (fr) | 2002-06-24 | 2012-09-19 | Genentech, Inc. | Variantes du ligand/Trail APO-2 et leurs utilisations |
| BRPI0509201A (pt) | 2004-03-23 | 2007-08-28 | Biogen Idec Inc | agentes de acoplamento de receptor e usos terapêuticos destes |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| US8029783B2 (en) | 2005-02-02 | 2011-10-04 | Genentech, Inc. | DR5 antibodies and articles of manufacture containing same |
| AU2006279618A1 (en) * | 2005-08-16 | 2007-02-22 | Genentech, Inc. | Apoptosis sensitivity to Apo2L/TRAIL by testing for 'GalNac-T14 expression in cells/tissues |
| WO2011008961A1 (fr) | 2009-07-15 | 2011-01-20 | Allegiance Corporation | Système de collecte et de mise au rebut de fluide et procédés associés |
| WO2012151317A1 (fr) | 2011-05-03 | 2012-11-08 | Genentech, Inc. | Agents d'interruption vasculaire et utilisations associées |
| WO2021058503A1 (fr) * | 2019-09-24 | 2021-04-01 | Centre National De La Recherche Scientifique - Cnrs - | Procédé d'identification de produits géniques impliqués dans une réponse incomplète de populations de cellules sensibles aux médicaments |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| WO1981001145A1 (fr) | 1979-10-18 | 1981-04-30 | Univ Illinois | Medicaments "pro-drugs" pouvant etre actives par des enzymes hydrolytiques |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| DE68925971T2 (de) | 1988-09-23 | 1996-09-05 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| EP0402226A1 (fr) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Vecteurs de transformation de la levure yarrowia |
| EP0479909B1 (fr) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Reactifs bispecifiques pour le traitement du sida |
| DE59010908D1 (de) | 1989-09-12 | 2000-08-10 | Hoffmann La Roche | TNF-bindende Proteine |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| IL99553A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing oligonucleotides linked to expression elements,a kit for the preparation of vectors useful for the expression of a diverse population of random peptides and methods utilizing the same |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
| WO1992020373A1 (fr) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Anticorps d'heteroconjugues pour le traitement des infections a l'hiv |
| WO1994004679A1 (fr) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Procede pour fabriquer des anticorps humanises |
| US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| WO1993008829A1 (fr) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions induisant la destruction de cellules infectees par l'hiv |
| ATE244763T1 (de) | 1992-02-11 | 2003-07-15 | Cell Genesys Inc | Erzielen von homozygotem durch zielgerichtete genetische ereignisse |
| DE69303494T2 (de) | 1992-11-13 | 1997-01-16 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| DE614989T1 (de) | 1993-02-17 | 1995-09-28 | Morphosys Proteinoptimierung | Verfahren für in vivo Selektion von Ligandenbindende Proteine. |
| DE69420137T2 (de) | 1993-06-03 | 1999-12-23 | Therapeutic Antibodies, Inc. | Herstellung von antikörperfragmenten |
| SE9304060D0 (sv) | 1993-12-06 | 1993-12-06 | Bioinvent Int Ab | Sätt att selektera specifika bakteriofager |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US5702892A (en) | 1995-05-09 | 1997-12-30 | The United States Of America As Represented By The Department Of Health And Human Services | Phage-display of immunoglobulin heavy chain libraries |
| KR100510234B1 (ko) | 1995-06-29 | 2005-11-25 | 임뮤넥스 코포레이션 | 세포소멸을 유도하는 시토킨 |
| ATE219517T1 (de) | 1995-08-18 | 2002-07-15 | Morphosys Ag | Protein-/(poly)peptidbibliotheken |
| US6030945A (en) * | 1996-01-09 | 2000-02-29 | Genentech, Inc. | Apo-2 ligand |
| JPH11507246A (ja) | 1996-03-20 | 1999-06-29 | ダイアックス コープ． | 巨大分子用アフィニティ・リガンドの設計 |
| WO1997044491A1 (fr) | 1996-05-22 | 1997-11-27 | The Johns Hopkins University | Procedes de detection au moyen de bacteriophage modifie |
| AU3381097A (en) | 1996-06-07 | 1998-01-05 | Amgen, Inc. | Tumor necrosis factor-related polypeptide |
| ATE279203T1 (de) | 1996-06-10 | 2004-10-15 | Scripps Research Inst | Verwendung von substrat-subtraktionsbibliotheken zur unterscheidung von enzymspezifitäten |
| WO1998005344A1 (fr) | 1996-08-05 | 1998-02-12 | Brigham And Women's Hospital, Inc. | Therapie genique a mediation par bacteriophages |
| JP2001512560A (ja) | 1996-10-08 | 2001-08-21 | ユー―ビスイス ベスローテン フェンノートシャップ | 標的に対し特異的な親和性を有するペプチドおよびタンパク質の選択のための方法および手段 |
| DK0939804T4 (da) | 1996-10-25 | 2011-07-18 | Human Genome Sciences Inc | Neutrokin-alpha |
| PT951551E (pt) | 1996-12-23 | 2008-10-28 | Immunex Corp | Ligando para receptor activador de nf-kb, ligando membro da superfamília de tnf |
| EP1012274B2 (fr) * | 1997-01-28 | 2011-06-15 | Human Genome Sciences, Inc. | Recepteur 4 (dr4:recepteur 4 de mort cellulaire) contenant des domaines de mort cellulaire, membre de la superfamille du recepteur du facteur de necrose tumorale (tnf) et se liant a la trail ( apo-2l) |
| US6072047A (en) | 1997-02-13 | 2000-06-06 | Immunex Corporation | Receptor that binds trail |
| US5969102A (en) | 1997-03-03 | 1999-10-19 | St. Jude Children's Research Hospital | Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof |
| US20010010924A1 (en) | 1997-03-14 | 2001-08-02 | Keith Charles Deen | Tumor necrosis factor related receptor, tr6 polynecleotides |
| DE69836956T2 (de) | 1997-03-17 | 2007-10-31 | Human Genome Sciences, Inc. | Rezeptor 5, der eine für den zelltod verantwortliche domäne enthält |
| SI0975754T2 (sl) | 1997-04-16 | 2016-04-29 | Amgen Inc., | Vezivni proteini in receptorji osteoprotegerina |
| EP1007562A4 (fr) | 1997-04-16 | 2000-09-27 | Millennium Pharm Inc | PROTEINES TANGO-63d ET TANGO-63e APPARENTEES AU RECEPTEUR DU FACTEUR DE NECROSE DES TUMEURS |
| EP1860187B1 (fr) | 1997-05-15 | 2011-07-13 | Genentech, Inc. | Récepteur apo-2 |
| WO1999002653A1 (fr) | 1997-07-11 | 1999-01-21 | Trustees Of The University Of Pennsylvania | Acide nucleique codant une nouvelle proteine induite par chimiotherapie, et ses procedes d'utilisation |
| WO1999004001A1 (fr) | 1997-07-21 | 1999-01-28 | Zymogenetics, Inc. | Recepteur ztnfr-5 du facteur de necrose tumorale |
| CA2297070A1 (fr) | 1997-08-01 | 1999-02-11 | Morphosys Ag | Nouvelle methode et nouveau phage d'identification d'une sequence d'acide nucleique |
| CA2299619A1 (fr) | 1997-08-06 | 1999-02-18 | Regeneron Pharmaceuticals, Inc. | Nouveau recepteur orphelin |
| AU8784498A (en) * | 1997-08-15 | 1999-03-08 | Idun Pharmaceuticals, Inc. | Trail receptors, nucleic acids encoding the same, and methods of use thereof |
| WO1999011791A2 (fr) | 1997-09-05 | 1999-03-11 | University Of Washington | Recepteurs et ligands de la famille du facteur de necrose tumorale, acides nucleiques codants et agents de liaison associes |
| AU2093499A (en) | 1997-12-30 | 1999-07-19 | Chiron Corporation | Members of tnf and tnfr families |
| PT1053256E (pt) * | 1998-01-26 | 2011-09-28 | Genentech Inc | Anticorpos para o receptor de morte 4 (dr4) e utilizações destes |
| IL138034A0 (en) * | 1998-03-27 | 2001-10-31 | Genentech Inc | Apo-2 ligand-anti-her-2 antibody synergism |
| ZA200002867B (en) * | 1999-06-09 | 2001-12-07 | Pfizer Prod Inc | Process for preparing sertraline from chiral tetralone. |
| KR102213110B1 (ko) | 2014-03-21 | 2021-02-09 | 에스케이플래닛 주식회사 | 끊김 없는 서비스를 위한 비콘 장치 및 그의 제어 방법 |
-
2001
- 2001-07-27 AT AT01957295T patent/ATE415978T1/de not_active IP Right Cessation
- 2001-07-27 AU AU2001279055A patent/AU2001279055A1/en not_active Abandoned
- 2001-07-27 EP EP08017358A patent/EP2014303A2/fr not_active Withdrawn
- 2001-07-27 DE DE60136816T patent/DE60136816D1/de not_active Expired - Lifetime
- 2001-07-27 IL IL15394801A patent/IL153948A0/xx unknown
- 2001-07-27 DK DK01957295T patent/DK1303293T3/da active
- 2001-07-27 CA CA002415473A patent/CA2415473A1/fr not_active Abandoned
- 2001-07-27 PT PT01957295T patent/PT1303293E/pt unknown
- 2001-07-27 ES ES01957295T patent/ES2317924T3/es not_active Expired - Lifetime
- 2001-07-27 EP EP01957295A patent/EP1303293B1/fr not_active Expired - Lifetime
- 2001-07-27 WO PCT/US2001/023691 patent/WO2002009755A2/fr not_active Ceased
- 2001-07-27 JP JP2002515307A patent/JP2004509078A/ja active Pending
-
2009
- 2009-02-18 CY CY20091100184T patent/CY1108815T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002009755A2 (fr) | 2002-02-07 |
| WO2002009755A3 (fr) | 2003-02-13 |
| DE60136816D1 (de) | 2009-01-15 |
| EP1303293B1 (fr) | 2008-12-03 |
| CA2415473A1 (fr) | 2002-02-07 |
| AU2001279055A1 (en) | 2002-02-13 |
| JP2004509078A (ja) | 2004-03-25 |
| PT1303293E (pt) | 2009-03-11 |
| CY1108815T1 (el) | 2014-04-09 |
| DK1303293T3 (da) | 2009-03-30 |
| EP2014303A2 (fr) | 2009-01-14 |
| EP1303293A2 (fr) | 2003-04-23 |
| ATE415978T1 (de) | 2008-12-15 |
| ES2317924T3 (es) | 2009-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL146491A0 (en) | APo-2L RECEPTOR AGONIST AND CPT-11 SYNERGISM | |
| CY1108815T1 (el) | Διαδοχικη χορηγηση cpt-11 και πολυπεπτιδιου apo-2l | |
| AP1913A (en) | Substituted benzazoles and use thereof as raf kinase inhibitors | |
| AP2002002458A0 (en) | Compounds for the treatment of ischemia. | |
| GB2389787B (en) | Mamalian animal composition | |
| AU2003298712A8 (en) | Methods and compositions for applying pharmacologic agents to the ear | |
| SG145699A1 (en) | Pyridazine derivatives and their use as therapeutic agents | |
| MY135766A (en) | Quinolinones and naphthyridinones for treating inflammatory diseases | |
| WO2002005797A8 (fr) | Utilisation d'agonistes du recepteur d2/d3 de la dopamine destine au traitement de la fibromyalgie | |
| AU7604400A (en) | Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents | |
| BR0016166A (pt) | Compostos de diidropirimidina heterocìclicos | |
| SG145700A1 (en) | Pyridyl derivatives and their use as therapeutic agents | |
| SG145695A1 (en) | Pyridyl derivatives and their use as therapeutic agents | |
| IL174965A0 (en) | SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE | |
| MXPA02004701A (es) | Sales de hidroxieicosatetraenoato, composiciones y metodos de uso para tratar trastornos de resequedad en los ojos. | |
| PL370657A1 (en) | Quinazolinone derivatives and their use as cb agonists | |
| EP1765873A4 (fr) | Utilisation combinee d'agoniste cd3 et de gastrine pour le traitement du diabete | |
| IL175303A0 (en) | Oral formulations for 5-ht-receptor agonists, uses and methods of treatment employing the same | |
| AU2001248971A1 (en) | Use of npy y1 receptor agonists in the treatment of pain conditions | |
| AU6022701A (en) | Use of substituted acryloyl distamycin derivatives in the treatment of tumors associated with high levels of glutathione | |
| EP1238095A4 (fr) | Compositions et methodes d'apoptose induite par caspase | |
| AU2003224808A8 (en) | Compositions and methods for delivering pharmaceutically active agents using nanoparticulates | |
| EA200200839A1 (ru) | Композиции с контролируемым высвобождением, содержащие агонист и антагонист опиоидов | |
| HUP0104820A3 (en) | Substituted benzimidazoles, production and use thereof as agents for combating parasitic protozoas | |
| AU2003257189A1 (en) | Methods and formulations useful for lowering the cholesterol content of egg yolk |